Abiomed, Inc. Sustainability Profile
Abiomed, Inc., a leading player in the cardiovascular medical device industry, is headquartered in the United States. Founded in 1981, the company has made significant strides in developing innovative heart pump technologies, particularly in the areas of heart recovery and circulatory support. With a focus on products such as the Impella heart pump, Abiomed has distinguished itself through its commitment to improving patient outcomes and advancing heart care. The company operates primarily in North America and Europe, positioning itself as a pioneer in minimally invasive heart pump solutions. Notable achievements include the FDA approval of its devices, which have transformed the treatment landscape for patients with severe coronary artery disease. Abiomed continues to lead the market with its cutting-edge technology and dedication to enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Abiomed, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abiomed, Inc.'s score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abiomed, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Johnson & Johnson, any climate commitments or emissions data would be inherited from its parent company. Abiomed is aligned with several climate initiatives through Johnson & Johnson, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Johnson & Johnson at a corporate family level. However, there are no specific reduction targets or achievements reported for Abiomed itself. The absence of direct emissions data suggests that Abiomed is still in the process of establishing its own climate commitments, while leveraging the sustainability framework and initiatives of Johnson & Johnson. This relationship indicates a commitment to broader corporate sustainability goals, although specific metrics for Abiomed's emissions and reduction targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Abiomed, Inc.'s Industry?
How Carbon Intensive is Abiomed, Inc.'s Location?
Abiomed, Inc.'s Scope 3 Categories Breakdown
Abiomed, Inc.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Abiomed, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abiomed, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
